DISTINCTIVE SIGNS OF (PC) DETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND WAYS OF THEIR APPLICATION

摘要

1. A method with a predetermined level of predictability, designed to assess the risk of relapse of a malignant tumor or the development of a metastatic malignant tumor in an individual, which includes:! but. measuring the level of two or more PC determinants selected from the group consisting of PC determinants 1-372 in a sample obtained from an individual; and! b. measuring a clinically significant change in the level of two or more PC-determinants in the sample, while this change indicates an increased risk of cancer recurrence or the development of a metastatic malignant tumor in an individual. ! 2. The method according to claim 1, in which two or more of these PC-determinants are selected from:! a) table 2; ! b) table 3; ! c) table 4; ! d) table 5; ! e) table 6; ! f) tables 7 and! g) two or more tables selected from tables 2-7. ! 3. The method of claim 1, wherein said PC determinants include PTEN, SMAD4, cyclin D1, and SPP1. ! 4. The method according to claim 1, which further includes measuring at least one standard parameter associated with the specified malignant tumor. ! 5. The method according to claim 4, in which the specified malignant tumor is prostate cancer and the specified standard parameter is a rating scale for Gliazon. ! 6. The method according to claim 1, in which the level of PC-determinants is measured by electrophoretic method, immunochemical method or non-invasive imaging method. ! 7. The method according to claim 6, in which the immunochemical detection method is a radioimmunoassay, immunofluorescence analysis or enzyme-linked immunosorbent assay. !8. The method according to claim 1, in which the individual has a primary tumor, tumor recurrence, or meta